EHang Announces Progress in EH216-S Type Certification Process as It Enters into More In-Depth Review Phase
September 30, 2022 10:07 ET
|
EHang Holdings Limited
GUANGZHOU, China, Sept. 30, 2022 (GLOBE NEWSWIRE) -- EHang Holdings Limited (Nasdaq: EH) (“EHang” or the “Company”), the world's leading autonomous aerial vehicle (“AAV”) technology platform...
Freeline Announces August 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 06, 2022 17:30 ET
|
Freeline Therapeutics Holdings plc
LONDON, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that on August 31, 2022, the Company granted two newly hired employees non-statutory...
EHang Reports Second Quarter 2022 Unaudited Financial Results
August 18, 2022 05:00 ET
|
EHang Holdings Limited
– Total Revenues Up 152.5% QoQ– High Quarterly Gross Margin of 67.1%– Indicative Facilities of RMB1 Billion by Agricultural Bank of China Guangzhou Branch– Increasing Deliveries in China and...
Freeline Reports Second Quarter 2022 Financial Results and Business Highlights
August 09, 2022 07:00 ET
|
Freeline Therapeutics Holdings plc
Six patients dosed in B-LIEVE trial of FLT180a in hemophilia B in four months and initial and emerging cohort one data reported, followed by NEJM publication of B-AMAZE long-term data Continued...
EHang to Report Second Quarter 2022 Unaudited Financial Results on Thursday, August 18, 2022
August 08, 2022 08:00 ET
|
EHang Holdings Limited
GUANGZHOU, China, Aug. 08, 2022 (GLOBE NEWSWIRE) -- EHang Holdings Limited (Nasdaq: EH) (“EHang” or the “Company”), the world’s leading autonomous aerial vehicle (“AAV”) technology platform company,...
Freeline Announces July 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 04, 2022 16:01 ET
|
Freeline Therapeutics Holdings plc
LONDON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that on July 29, 2022, the Company granted its newly hired Chief People Officer Nicole...
EH216 Completes Demo Flight Tour in 4 Japanese Cities to Mark 1,000-Day Countdown of Expo 2025 Osaka, Kansai
July 22, 2022 08:38 ET
|
EHang Holdings Limited
GUANGZHOU, China, July 22, 2022 (GLOBE NEWSWIRE) -- EHang Holdings Limited (Nasdaq: EH) (“EHang” or the “Company”), the world's leading autonomous aerial vehicle (“AAV”) technology platform company,...
New England Journal of Medicine Publishes Positive Long-Term Data on Freeline’s Gene Therapy Candidate FLT180a for People with Hemophilia B
July 21, 2022 07:00 ET
|
Freeline Therapeutics
LONDON, July 21, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that the New England Journal of Medicine (NEJM) published positive data that expand upon...
Frontera Therapeutics Completes $160 Million Series B Financing to Fund Clinical Development and Manufacturing Capabilities
July 19, 2022 08:00 ET
|
Frontera Therapeutics
FDA clears Investigational New Drug (IND) application for lead gene therapy product candidate, FT-001, for the treatment of a rare inherited eye disease leading to severe visual impairment that may...
Freeline Announces June 2022 Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
July 01, 2022 16:01 ET
|
Freeline Therapeutics
LONDON, July 01, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that on June 30, 2022, the Company granted a newly hired employee non-statutory options to...